AP2965A - Therapeutic compositions and the use thereof - Google Patents

Therapeutic compositions and the use thereof

Info

Publication number: AP2965A
Authority: AP; ARIPO
Prior art keywords: therapeutic compositions; therapeutic; compositions
Prior art date: 2007-06-29

Application number

AP2009005074A

Other languages

English (en)

Other versions

AP2009005074A0 (en

Inventor

Brian P Kearney

Anita A Mathias

Srinivasan Ramanathan

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-29

Filing date

2008-06-26

Publication date

2014-09-30

2008-06-26 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2009-12-31 Publication of AP2009005074A0 publication Critical patent/AP2009005074A0/en

2014-09-30 Application granted granted Critical

2014-09-30 Publication of AP2965A publication Critical patent/AP2965A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Quinoline Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AP2009005074A 2007-06-29 2008-06-26 Therapeutic compositions and the use thereof AP2965A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US94730607P	2007-06-29	2007-06-29
US4092008P	2008-03-31	2008-03-31
PCT/US2008/068339 WO2009006199A1 (en)	2007-06-29	2008-06-26	Therapeutic compositions and the use thereof

Publications (2)

Publication Number	Publication Date
AP2009005074A0 AP2009005074A0 (en)	2009-12-31
AP2965A true AP2965A (en)	2014-09-30

Family

ID=39831893

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2009005074A AP2965A (en)	2007-06-29	2008-06-26	Therapeutic compositions and the use thereof

Country Status (19)

Country	Link
US (4)	US20100331331A1 (pt)
EP (1)	EP2167088A1 (pt)
JP (3)	JP5547066B2 (pt)
KR (1)	KR20100040892A (pt)
CN (2)	CN101686972B (pt)
AP (1)	AP2965A (pt)
AR (1)	AR067183A1 (pt)
AU (1)	AU2008270630B2 (pt)
BR (1)	BRPI0813000A2 (pt)
CA (1)	CA2692101A1 (pt)
CO (1)	CO6251237A2 (pt)
EA (1)	EA200971093A1 (pt)
EC (1)	ECSP109897A (pt)
IL (1)	IL202744A0 (pt)
MX (1)	MX2009013829A (pt)
NZ (1)	NZ582086A (pt)
SG (1)	SG182229A1 (pt)
TW (1)	TW200914011A (pt)
WO (1)	WO2009006199A1 (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG170795A1 (en) *	2005-12-30	2011-05-30	Gilead Sciences Inc	Methods for improving the pharmacokinetics of hiv integrase inhibitors
ME02258B (me)	2006-07-07	2015-12-31	Gilead Sciences Inc	Modulatori farmakokinetičkih svojstava terapeutika
TWI411602B (zh)	2006-09-12	2013-10-11	Gilead Sciences Inc	製造整合酶抑制劑的方法及彼所用的中間物
PL2487161T5 (pl) *	2007-02-23	2024-09-09	Gilead Sciences, Inc.	<div>Modulatory właściwości farmakokinetycznych środków terapeutycznych</div><div> </div>
NZ582089A (en) *	2007-06-29	2013-01-25	Gilead Sciences Inc	Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
TW200914011A (en) *	2007-06-29	2009-04-01	Gilead Sciences Inc	Therapeutic compositions and methods
AR068403A1 (es)	2007-09-11	2009-11-18	Gilead Sciences Inc	Proceso e intermediarios para la preparacion de inhibidores de integrasa
PL2296633T3 (pl)	2008-05-02	2016-03-31	Gilead Sciences Inc	Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego
EP2555757B1 (en) *	2010-04-09	2016-05-25	Bristol-Myers Squibb Holdings Ireland	Atazanavir sulfate formulations with improved ph effect
US20130274254A1 (en) *	2010-12-21	2013-10-17	Gilead Sciences, Inc.	Inhibitors of cytochrome p450 (cyp3a4)
WO2013082476A1 (en)	2011-11-30	2013-06-06	Emory University	Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
AU2013296289B2 (en)	2012-08-03	2017-10-05	Gilead Sciences, Inc.	Process and intermediates for preparing integrase inhibitors
PE20151499A1 (es)	2012-12-21	2015-10-29	Gilead Sciences Inc	Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico
NO2865735T3 (pt)	2013-07-12	2018-07-21
EP3252058B1 (en)	2013-07-12	2021-01-20	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
US9463194B2 (en)	2014-02-05	2016-10-11	Gilead Sciences, Inc.	Methods of treating patients co-infected with HIV and tuberculosis
TWI744723B (zh)	2014-06-20	2021-11-01	美商基利科學股份有限公司	多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en)	2014-06-20	2016-04-16	Gilead Sciences Inc	Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (pt)	2014-06-20	2018-06-23
TWI695003B (zh)	2014-12-23	2020-06-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
US20190022116A1 (en)	2014-12-26	2019-01-24	Emory University	N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto
KR20190057158A (ko)	2015-04-02	2019-05-27	길리애드 사이언시즈, 인코포레이티드	폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
DK3706762T3 (da)	2017-12-07	2024-12-16	Univ Emory	N4-hydroxycytidin og derivater og antivirale anvendelser relateret dertil

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020004059A1 (en) *	1998-07-29	2002-01-10	Juanita Elena Van Koppenhagen	Base-triggered release microcapsules
WO2005113508A1 (en) *	2004-05-20	2005-12-01	Japan Tobacco Inc.	Stable crystal of 4-oxoquinoline compound
WO2006034001A2 (en) *	2004-09-16	2006-03-30	Bristol-Myers Squibb Company	Methods of treating hiv infection

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5552558A (en) *	1989-05-23	1996-09-03	Abbott Laboratories	Retroviral protease inhibiting compounds
GB8927913D0 (en) *	1989-12-11	1990-02-14	Hoffmann La Roche	Amino acid derivatives
US5413999A (en) *	1991-11-08	1995-05-09	Merck & Co., Inc.	HIV protease inhibitors useful for the treatment of AIDS
US5484926A (en) *	1993-10-07	1996-01-16	Agouron Pharmaceuticals, Inc.	HIV protease inhibitors
US5914332A (en) *	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
US5849911A (en) *	1996-04-22	1998-12-15	Novartis Finance Corporation	Antivirally active heterocyclic azahexane derivatives
US6087383A (en) *	1998-01-20	2000-07-11	Bristol-Myers Squibb Company	Bisulfate salt of HIV protease inhibitor
DE60329318D1 (de) *	2002-11-20	2009-10-29	Japan Tobacco Inc	4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
EP3287130A1 (en) *	2004-05-21	2018-02-28	Japan Tobacco Inc.	Combinations comprising a 4-isoquinolone derivative and protease inhibitors
SG170795A1 (en) *	2005-12-30	2011-05-30	Gilead Sciences Inc	Methods for improving the pharmacokinetics of hiv integrase inhibitors
US20090233964A1 (en) *	2005-12-30	2009-09-17	Gilead Sciences, Inc.	Methods for improving the pharmacokinetics of hiv integrase inhibitors
ME02258B (me) *	2006-07-07	2015-12-31	Gilead Sciences Inc	Modulatori farmakokinetičkih svojstava terapeutika
TWI411602B (zh) *	2006-09-12	2013-10-11	Gilead Sciences Inc	製造整合酶抑制劑的方法及彼所用的中間物
NZ582089A (en) *	2007-06-29	2013-01-25	Gilead Sciences Inc	Antiviral Combination of elvitegravir, lopinavir and optionally ritonavir
TW200914011A (en) *	2007-06-29	2009-04-01	Gilead Sciences Inc	Therapeutic compositions and methods
AR068403A1 (es) *	2007-09-11	2009-11-18	Gilead Sciences Inc	Proceso e intermediarios para la preparacion de inhibidores de integrasa
PL2296633T3 (pl) *	2008-05-02	2016-03-31	Gilead Sciences Inc	Zastosowanie cząsteczek stałych nośników dla udoskonalenia przetwarzalności środka farmaceutycznego
US20110000941A1 (en) *	2009-07-06	2011-01-06	Volk J Patrick	Apparatus and System for Carrying a Digital Media Player

2008
- 2008-06-26 TW TW097123983A patent/TW200914011A/zh unknown
- 2008-06-26 KR KR1020107001981A patent/KR20100040892A/ko not_active Ceased
- 2008-06-26 AU AU2008270630A patent/AU2008270630B2/en not_active Ceased
- 2008-06-26 SG SG2012046934A patent/SG182229A1/en unknown
- 2008-06-26 WO PCT/US2008/068339 patent/WO2009006199A1/en not_active Ceased
- 2008-06-26 US US12/666,991 patent/US20100331331A1/en not_active Abandoned
- 2008-06-26 US US12/147,041 patent/US20090093467A1/en not_active Abandoned
- 2008-06-26 EA EA200971093A patent/EA200971093A1/ru unknown
- 2008-06-26 CA CA002692101A patent/CA2692101A1/en not_active Abandoned
- 2008-06-26 AP AP2009005074A patent/AP2965A/xx active
- 2008-06-26 JP JP2010515112A patent/JP5547066B2/ja not_active Expired - Fee Related
- 2008-06-26 AR ARP080102759A patent/AR067183A1/es not_active Application Discontinuation
- 2008-06-26 CN CN2008800228167A patent/CN101686972B/zh not_active Expired - Fee Related
- 2008-06-26 CN CN201310302662.XA patent/CN103480000A/zh active Pending
- 2008-06-26 MX MX2009013829A patent/MX2009013829A/es unknown
- 2008-06-26 BR BRPI0813000-0A2A patent/BRPI0813000A2/pt not_active IP Right Cessation
- 2008-06-26 NZ NZ582086A patent/NZ582086A/en not_active IP Right Cessation
- 2008-06-26 EP EP08772024A patent/EP2167088A1/en not_active Withdrawn
2009
- 2009-12-15 IL IL202744A patent/IL202744A0/en unknown
- 2009-12-21 CO CO09146055A patent/CO6251237A2/es not_active Application Discontinuation
2010
- 2010-01-22 EC EC2010009897A patent/ECSP109897A/es unknown
2013
- 2013-07-08 JP JP2013142322A patent/JP5769763B2/ja not_active Expired - Fee Related
2014
- 2014-05-19 US US14/281,798 patent/US20140343063A1/en not_active Abandoned
2015
- 2015-05-07 JP JP2015094707A patent/JP2015143278A/ja not_active Withdrawn
2016
- 2016-10-19 US US15/298,084 patent/US20170136001A1/en not_active Abandoned

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020004059A1 (en) *	1998-07-29	2002-01-10	Juanita Elena Van Koppenhagen	Base-triggered release microcapsules
WO2005113508A1 (en) *	2004-05-20	2005-12-01	Japan Tobacco Inc.	Stable crystal of 4-oxoquinoline compound
WO2006034001A2 (en) *	2004-09-16	2006-03-30	Bristol-Myers Squibb Company	Methods of treating hiv infection

Also Published As

Publication number	Publication date
US20140343063A1 (en)	2014-11-20
CO6251237A2 (es)	2011-02-21
IL202744A0 (en)	2010-06-30
JP2010532372A (ja)	2010-10-07
CN101686972B (zh)	2013-08-14
AU2008270630B2 (en)	2014-01-16
JP2015143278A (ja)	2015-08-06
CA2692101A1 (en)	2009-01-08
JP5547066B2 (ja)	2014-07-09
US20090093467A1 (en)	2009-04-09
MX2009013829A (es)	2010-03-10
JP2013199495A (ja)	2013-10-03
ECSP109897A (es)	2010-03-31
US20100331331A1 (en)	2010-12-30
KR20100040892A (ko)	2010-04-21
JP5769763B2 (ja)	2015-08-26
TW200914011A (en)	2009-04-01
BRPI0813000A2 (pt)	2014-12-23
US20170136001A1 (en)	2017-05-18
CN103480000A (zh)	2014-01-01
EA200971093A1 (ru)	2010-08-30
CN101686972A (zh)	2010-03-31
AP2009005074A0 (en)	2009-12-31
EP2167088A1 (en)	2010-03-31
AU2008270630A1 (en)	2009-01-08
NZ582086A (en)	2012-07-27
WO2009006199A1 (en)	2009-01-08
SG182229A1 (en)	2012-07-30
AR067183A1 (es)	2009-09-30

Publication	Publication Date	Title
AP2965A (en)	2014-09-30	Therapeutic compositions and the use thereof
AP2490A (en)	2012-10-04	Therapeutic compositions and the use thereof
GB0719803D0 (en)	2007-11-21	Therapeutic compounds and their use
GB0719644D0 (en)	2007-11-14	Therapeutic compounds and their use
GB0625659D0 (en)	2007-01-31	Therapeutic compounds and their use
GB0701426D0 (en)	2007-03-07	Compounds and their use
PL2185552T3 (pl)	2014-08-29	Proleki dipeptoidowe i ich zastosowanie
GB0724251D0 (en)	2008-02-06	Therapeutic compounds and their use
ZA200902189B (en)	2010-02-24	Phenylpropionamide compounds and the use thereof
IL202073A0 (en)	2010-06-16	Substituted oxazolidinones and the use thereof
GB0722680D0 (en)	2007-12-27	Therapeutic compounds and their use
EP2307052A4 (en)	2012-08-01	ANTI-BETA-2-MICROGLOBULIN AGENTS AND THEIR USE
PL2012805T3 (pl)	2014-01-31	Kompozycja lecznicza i jej zastosowanie
EP2170874A4 (en)	2011-08-31	NEW COMPOUNDS AND THEIR USE
EP2231163A4 (en)	2012-10-31	COMPOUNDS AND THEIR THERAPEUTIC USE
GB0808690D0 (en)	2008-06-18	Therapeutic use
GB0714500D0 (en)	2007-09-05	composition and treatment
ZA201000469B (en)	2010-09-29	Therapeutic compositions and the use thereof
GB0705517D0 (en)	2007-05-02	Therapeutic compounds and their use
HK1141722A (en)	2010-11-19	Therapeutic compositions and the use thereof
HK1141721A (en)	2010-11-19	Therapeutic compositions and the use thereof
GB0614538D0 (en)	2006-08-30	Therapeutic Compounds And Their Use
GB0608797D0 (en)	2006-06-14	Novel agents and the use thereof
GB0711465D0 (en)	2007-07-25	Silan-3-amines and disilan-5-amines as therapeutic agents
GB0720524D0 (en)	2007-11-28	Compositions and their use